Posts Tagged ‘vaccine’

Is CNN sug­gest­ing man­di­tory vaccinations?

September 6th, 2009

Mos­qui­toes deliver malaria ‘vac­cine’ through bites

July 30th, 2009

The results were astound­ing: Every­one in the vac­cine group acquired immu­nity to malaria; every­one in a non-vaccinated com­par­i­son group did not, and devel­oped malaria when exposed to the par­a­sites later.

The study was only a small proof-of-principle test, and its approach is not prac­ti­cal on a large scale. How­ever, it shows that sci­en­tists may finally be on the right track to devel­op­ing an effec­tive vac­cine against one of mankind’s top killers. A vac­cine that uses mod­i­fied live par­a­sites just entered human testing.

“Malaria vac­cines are mov­ing from the lab­o­ra­tory into the real world,” Dr. Car­los Camp­bell wrote in an edi­to­r­ial accom­pa­ny­ing the study in Thursday’s New Eng­land Jour­nal of Med­i­cine. He works for PATH, the Pro­gram for Appro­pri­ate Tech­nol­ogy in Health, a Seattle-based global health foun­da­tion. [ ]

» Read more: Mos­qui­toes deliver malaria ‘vac­cine’ through bites

Swine Flu Shot in U.S. May Rely on Emer­gency Use of Additives

July 29th, 2009

July 29 (Bloomberg) — Swine flu vac­cine mak­ers may rely on a U.S. emer­gency dec­la­ra­tion to use exper­i­men­tal addi­tives made by Glax­o­SmithK­line Plc and Novar­tis AG to boost a lim­ited sup­ply of shots that will be avail­able to fight the pandemic.

The ingre­di­ents, known as adju­vants, may be added for the first time to flu shots in the U.S. Health offi­cials, meet­ing today at the U.S. Cen­ters for Dis­ease Con­trol and Pre­ven­tion in Atlanta, plan to dis­cuss use of the addi­tives, and may also rec­om­mend who should be first to receive the lim­ited amount of vac­cines drug­mak­ers say they will begin deliv­er­ing in October.

The U.S. Health and Human Ser­vices Depart­ment declared a pub­lic health emer­gency over swine flu in April, and the Food and Drug Admin­is­tra­tion has the power to allow the use of unap­proved med­ical prod­ucts dur­ing such a cri­sis. The U.S. has been slow to approve the use of adju­vants because of safety con­cerns, and for fear of giv­ing Amer­i­cans an excuse to avoid get­ting the shots, said John Tre­anor, a Uni­ver­sity of Rochester researcher. [ ]

» Read more: Swine Flu Shot in U.S. May Rely on Emer­gency Use of Additives

The cur­rent threat of swine flu doesn’t jus­tify a gam­ble on a vac­cine that has not been fully tested

July 22nd, 2009

A mass vac­ci­na­tion pro­gram moves ever closer. Orders have been placed; pri­or­ity groups iden­ti­fied. There will be enough swine flu vac­cine to inoc­u­late the entire pop­u­la­tion, start­ing with NHS staff, in an attempt to halt the spread of the dis­ease and save lives.

Is all this really nec­es­sary? To start with, swine flu is far milder than we first feared, so the case for vac­ci­nat­ing mil­lions of healthy adults against a dis­ease that is no more unpleas­ant than a bad cold is ques­tion­able. There is a stronger argu­ment for vac­ci­nat­ing those at greater risk, such as those with lung, heart or kid­ney dis­ease, those with sup­pressed immune sys­tems (such as those on can­cer treat­ment), preg­nant women and chil­dren under 5 — but only if the vac­cine works and is safe. But there are seri­ous doubts about this.

Rush­ing the vac­cine on to the mar­ket means we will have no idea how effec­tive it is, although we do have a body of research on the effec­tive­ness of flu vac­cines in gen­eral, which gives some idea of what we might expect from the swine flu vac­cine. Pro­vided that we have matched the vac­cine well with the virus, it is likely to be up to 80 per cent effec­tive in healthy adults, the group at least risk from the virus.

A num­ber of tri­als have looked at the effect of flu vac­ci­na­tion on children’s asthma and have failed to demon­strate any ben­e­fit; one trial even sug­gested that the vac­cine made asthma worse. There is no good evi­dence that the vac­cine helps those with chronic health prob­lems or preg­nant women. How­ever, we do know that the immu­ni­sa­tion offers no more than a mod­est ben­e­fit in the elderly; indeed, the effec­tive­ness of the vac­cine is known to decrease sharply after 70 years of age.

The first vac­cines are expected to arrive in the UK by the end of next month. It will be some weeks later before they have gone through the min­i­mal safety test­ing nec­es­sary to con­sider offer­ing them to the gen­eral pop­u­la­tion. Real­is­ti­cally, it is unlikely that suf­fi­cient doses will arrive to vac­ci­nate sub­stan­tial num­bers until the end of the year.

Full story at Times Online